Full-Time

Senior Research Associate

In Vitro Assay Development & High-throughput Screening

Posted on 8/15/2024

Remix Therapeutics

Remix Therapeutics

51-200 employees

Develops mRNA-based treatments for rare diseases

Biotechnology
Healthcare

Mid, Senior

Belmont, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • BS, M.Sc. or equivalent in biochemistry, biophysics, or a related discipline with 4-6+ years of experience working in a pharmaceutical/biotechnology laboratory setting
  • Experience running multi-well plate-based *in vitro* assays with fluorescent/luminescent readouts (e.g. TR-FRET, FP) at various scales
  • Experience working with laboratory automation, HTS, Hit-to-Lead, and compound management workflows is required
  • Familiarity with various biochemical and biophysical techniques (including cutting-edge technologies e.g., SPR/GCI, MST, DSF, etc.) is desired
Responsibilities
  • Execute high-throughput screening campaigns with small molecule libraries
  • Design and develop *in vitro* assays to screen/profile the binding and complex kinetics of small molecule compounds to large protein complexes
  • Evaluate and implement novel biochemical and biophysical technologies for target and hit discovery
  • Interpret, present, and report research findings in an open and timely manner
  • Build and maintain productive relationships with colleagues in biomolecular sciences, biology, and chemistry

Remix Therapeutics focuses on creating treatments for rare and difficult diseases, particularly targeting rare cancers and genetic disorders. Their main product, REM 422, is an oral small molecule that works by degrading messenger RNA (mRNA), which can stop the production of harmful proteins linked to these diseases. Currently, REM 422 is undergoing Phase 1 clinical trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, and it has received Orphan Drug Designation from the FDA, which offers benefits for drugs treating rare conditions. Unlike many competitors, Remix Therapeutics emphasizes a strong research and development approach, funding their work through grants and partnerships, with the goal of bringing new medicines to patients inspired by personal experiences with serious illnesses.

Company Stage

Growth Equity (Venture Capital)

Total Funding

$205.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

1%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Roche could yield up to $1 billion in milestone payments.
  • Recent $90 million financing boosts R&D and expansion efforts.
  • REM 422 shows promising preclinical results in AML and ACC treatments.

What critics are saying

  • Potential competition from other RNA-targeting biotech companies.
  • High costs and lengthy clinical trials may strain financial resources.
  • Regulatory hurdles could delay RNA-targeting drug approvals.

What makes Remix Therapeutics unique

  • Remix uses REMaster platform to modulate RNA processing for disease treatment.
  • REM 422 is a first-in-class MYB mRNA degrader for cancer treatment.
  • FDA granted Orphan Drug Designation to REM 422 for rare diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE